Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL).
Hodson DJ, Shouse G, Shin HJ, Salar A, Bobillo S, Ribrag V, Macpherson NA, Cordoba R, Kim JS, Guidez S, Herrera AF, Morschhauser F, Colton D, Izuzquiza M, Sambamurthy N, Munugalavadla V, Vicente S, Gorgun G, Chen R, Younes A, Wang ML.
Hodson DJ, et al. Among authors: kim js.
Clin Cancer Res. 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-2239. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 41427952